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Abstract
Urinary metabolites of tobacco smoke toxins are often used as
biomarkers for the evaluation of active and passive exposure
to cigarette smoke toxins. In a study of healthy smokers, we
investigated concentrations of urinary biomarkers in relation
to concentrations of selected toxins in mainstream cigarette
smoke as determined by machine smoking of cigarettes in a
manner that mimics an individual’s smoking behavior
(topography). Concentrations of nicotine, 4-(methylnitrosa-
mino)-1-(3-pyridyl)-1-butanone, and benzo(a)pyrene, in
mainstream smoke determined under human smoking con-
ditions, and their urinary metabolites cotinine, 4-(methylni-
trosamino)-1-(3-pyridyl)-1-butanol, and 1-hydroxypyrene
were established for 257 individuals who smoked low-yield
(0.1-0.8 mg Federal Trade Commission nicotine/cigarette;
mean, 0.66; n = 87), medium-yield (0.9-1.2 mg nicotine/
cigarette; mean, 1.1; n = 109), and high-yield cigarettes
(nicotine, >1.3 mg nicotine/cigarette; mean, 1.41; n = 61).
Levels of urinary metabolites expressed per unit of delivered
parent compounds decreased with increased smoke emis-
sions. In smokers of low-, medium-, and high-yield cigarettes,
the respective cotinine (ng/mg creatinine)-to-nicotine (mg/d)
ratios were 89.4, 77.8, and 57.1 (low versus high; P = 0.06); the
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (pmol/mg
creatinine)-to-4-(methylnitrosamino)-1-(3-pyridyl)-1-buta-
none (ng/d) ratios were 0.81, 0.55, and 0.57 (low versus high;
P = 0.05); and the 1-hydroxypyrene (pg/mg creatinine)-
to-benzo(a)pyrene (ng/d) ratios were 1.55, 1.13, and 0.97
(low versus high; P = 0.008). Similarly, means of cotinine
per unit of delivered nicotine in smokers who consumed
<20 cigarettes per day was 3.5-fold higher than in those who
smoked >20 cigarettes per day. Likewise, a negative correla-
tion was observed between cotinine-to-nicotine ratios and
delivereddoses of nicotine in subgroups of smokerswhoused
the identical brand of cigarette, namely a filter tip-vented
Marlboro (r = 0.59), which is a popular brand among Euro-
Americans, and Newport (r = 0.37), a menthol-flavored
cigarette without filter tip vents that is preferred by African-
Americans. Thus, the intensity of the exposures significantly
affects the levels of urinary biomarkers of exposure and
should be taken into account in the evaluation of human
exposure to cigarette smoke toxins. (Cancer Epidemiol
Biomarkers Prev 2007;16(7):1408–15)
Introduction
The association of cigarette smoking with the risk for various
human cancers, chronic obstructive pulmonary disease, and
cardiovascular disease is well established (1, 2). Epidemiologic
studies have also shown a dose-response relationship between
cigarette smoking and adverse health outcomes based on
smoking intensity and duration of smoking (1, 2). Thus, one
would anticipate a relationship between exposure to tobacco
toxins and disease risk.
Cigarette smoke is a highly complex matrix with almost
4,800 constituents identified (1). More than sixty of the
identified compounds, including polynuclear aromatic hydro-
carbons (PAH) and tobacco-specific N-nitrosamines, are
classified as carcinogens by the IARC based on evidence in
humans and/or animals (1). The delivered dosage of tobacco
smoke compounds is influenced not only by cigarette
composition and design but also by many smoker-dependent
variables, such as number of cigarettes smoked per day,
puffing patterns, blocking of filter vents, and length of
cigarette smoked (3-5). The delivery of specific toxic constit-
uents from each cigarette smoked by an individual can be
determined by machine smoking that individual’s particular
brand of cigarette under conditions that mimic their specific
puffing pattern, butt lengths, and blocking of the filter vents
(6, 7). Puffing parameters (topography) are usually assessed
using a computer-assisted flow transducer that determines the
flow of smoke from a lit cigarette as it is smoked (6, 7). Internal
exposure can also be assessed in individual smokers by
measuring the sum of toxins and their metabolites in
appropriate biological fluids. However, although urinary
metabolites are commonly used to evaluate smokers’ exposure
to nicotine and carcinogens, interpretation of these biomarker
levels are complicated by interindividual differences in
metabolism (8-12). The availability of more than one thousand
brands on the market [e.g., 1,294 brands in the United States in
1998; Federal Trade Commission (FTC) report issued in 2000],
the variety of ways in which smokers use the same or different
products, and the influence of gender, race, and age on
metabolism of toxins challenge the accurate evaluation of
smokers’ exposure to cigarette smoke toxins.
The goal of this study is to examine the relationships
between delivered dosages of smoke constituents, such as
nicotine and select carcinogens, determined using actual
human smoking conditions and levels of corresponding
urinary metabolites in smokers. The effect of cigarette brand
and associated yield (FTC) of nicotine and tar on these
relationships will also be examined. To this end, we measured
the delivery of nicotine and select cigarette smoke constituents
among adult smokers as described earlier (6, 7) and deter-
mined the levels of corresponding metabolites in urine.
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Specifically, we quantified nicotine, 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK), and benzo(a)pyrene (BaP; as a
marker of exposure to PAH) in the mainstream smoke
condensate generated by machine smoking of each individu-
al’s cigarettes under conditions that reflect that individual’s
smoking pattern. Levels of urinary cotinine were determined
for nicotine exposure, and 4-(methylnitrosamino)-1-(3-pyr-
idyl)-1-butanol (NNAL) was used as a marker for NNK,
whereas 1-hydroxypyrene (1-OH-P) was quantified as a
biomarker for PAH exposures.
Materials and Methods
Study Subjects and Sample Collection. In this community-
based study, adult volunteers between 18 and 59 years of age
and in good general health were recruited from the local
community as described previously (7, 13). These volunteers
were screened by telephone to determine whether they met the
following specific criteria: they had to have smoked at least
10 cigarettes of their current brand daily for at least 1 year and
had to be in good health, without a history of any tobacco-
related disease, and without any unstable medical condition.
Also they had to be free from psychotropic medications and
without any psychiatric diagnosis at the time of study. They
were not eligible if they were using any tobacco- or nicotine-
containing products other than cigarettes for at least 3 months
before the study. Pregnant and nursing women were excluded
from the study. To our knowledge, those who enrolled in this
study were not participating to any tobacco cessation program
or seeking any type of treatment.
Subjects enrolled in the study voluntarily in response to
newspaper advertisements in Westchester County, New York,
and remunerated for their participation. All subjects gave
written consent, and the study was approved by the American
Health Foundation’s Institutional Human Subjects Review
Committee in accordance with assurances filed with and
approved by the U.S. Department of Health and Human
Services.
A telephone interview determined initial eligibility. Eligible
volunteers were enrolled and received detailed information
about study goals and procedures. On signing consent, they
were asked to collect cigarette butts for a total of 4 days before
their visit. The butts were used to validate the subject’s self-
reported number of cigarettes smoked per day, to assess the
average length of each cigarette smoked, and to evaluate
whether blocking of the air vents of filter tips had occurred
during smoking. A trained interviewer administered a
comprehensive questionnaire to obtain information on smok-
ing history, namely the age at onset of smoking, the quantity
and type of cigarettes and number of years smoked,
occupational exposure, family medical history, diet and other
lifestyle factors, as well as nicotine dependence using the
Fagerstrom questionnaire. During the interview, volunteers
disclosed the brand of cigarettes they smoked, type of pack
(hard or soft), and whether they smoked mentholated or
nonmentholated cigarettes. Detailed cigarette brand informa-
tion was obtained to assign the correct FTC smoke yield
because several varieties with different FTC smoke yields are
marketed under the same brand name.
Most smoking measurements were carried out between
10:00 a.m. and 1:00 p.m. A single urine sample was collected
from each smoker about the same time of the day after they
smoked three or four cigarettes for smoking topography
measurements (7).
About half of the subjects were recruited within years 2001
and 2002 and the other major recruitment was in the years 1997
and 1998. Each smoker’s cigarettes were purchased at the same
time the urine sample was collected.
Measurement of Toxic and Carcinogenic Compounds in
Emissions of Mainstream Smoke. The smoking parameters
were determined by means of a computer-assisted pressure
transducer system as described previously (6, 7). Each
individual’s brand of cigarette was then machine smoked
with his or her average smoking parameters, including
blocking of the filter tip vents and specific butt length. For
determination of each analyte, the smoke particulates from
four cigarettes were collected on a Cambridge filter pad and
analyzed as described below.
Nicotine content in smoke particulate was analyzed by gas
chromatography using a nitrogen phosphorous detector (6, 7,
14, 15), NNK concentrations were determined by gas chroma-
tography using a thermal energy analyzer as a detector (gas
chromatography with nitrosamine-selective detection; ref. 16),
and BaP was determined by gas chromatography-mass
spectrometry (17).
Analysis of Urinary Biomarkers
Simultaneous Determination of Nonconjugate Urinary 1-OH-P,
1-OH-P Glucuronide Conjugate, and 1-OH-P-Sulfate Conjugate.
Free and conjugated 1-OH-P were analyzed by modification of
Table 1. Demographic information for study subjects
Variables ALL AA EA P
Female Male Female Male Female Male (Female vs male)






129 128 57 55 72 73
Age (y) 33.1 (31.2-35.0) 35.0 (33.3-36.9) 34.4 (31.8-37.3) 36.4 (34.0-39.1) 32.1 (29.6-34.8) 34.1 (31.7-36.6) 0.14 0.29 0.28
Body mass index 25.5 (24.5-26.5) 26.8 (26.1-27.4) 27.6 (26.0-29.4) 27.3 (26.2-28.4) 24.0 (22.9-25.1) 26.4 (25.6-27.2) 0.06 0.74 0.0007
Cigarettes per day 15.9 (14.7-17.1) 16.8 (15.5-18.2) 14.3 (12.8-16.0) 14.1 (12.8-15.6) 17.2 (15.6-19.0) 19.1 (17.1-21.4) 0.42 0.83 0.17
Age at onset of
smoking (y)
15.3 (14.7-15.8) 16.4 (15.8-17.0) 15.8 (14.8-16.8) 16.6 (15.8-17.5) 14.9 (14.3-15.5) 16.3 (15.5-17.1) 0.008 0.2 0.009
Years smoked 14.9 (13.2-16.9) 15.8 (14.0-17.9) 15.7 (13.2-18.5) 17.4 (14.9-20.4) 14.3 (12.0-17.1) 14.8 (12.4-17.6) 0.44 0.37 0.81
Fagerstro¨m index 4.11 (3.65-4.62) 4.57 (4.12-5.06) 4.12 (3.49-4.89) 4.28 (3.69-4.93) 4.09 (3.46-4.80) 4.80 (4.16-5.52) 0.23 0.78 0.15
Length of cigarette
smoked (mm)
54.1 (52.7-55.5) 53.2 (51.7-54.9) 57.3 (55.1-59.6) 55.3 (52.8-57.9) 51.7 (50.1-53.4) 51.8 (49.9-53.9) 0.39 0.24 0.93
Butt length (mm) 36.3 (35.4-37.2) 34.3 (33.4-35.2) 34.5 (33.4-35.5) 33.9 (32.4-35.4) 37.8 (36.5-39.1) 34.6 (33.4-35.8) 0.005 0.53 0.0005
Cigarette type:
mentholated
50% 50% 88% 80% 21% 27%
NOTE: Data are presented in geometric mean and 95% CI.
Abbreviations: GM, geometric mean; AA, African-Americans; EA, Euro-Americans.
*P values are adjusted for race using ANOVA models.
cP values are based on Student’s t test.
bA total of 257 subjects were included in the analysis, after excluding 5 subjects whose cotinine levels were <130 ng/mL.
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a method reported previously (18, 19). The procedure is
designed to quantify simultaneously 1-OH-P glucuronide
(1-OH-P-gluc) conjugate, 1-OH-P-sulfate (1-OH-P-sulf), and
free 1-OH-P. In brief, each urine sample (1.5 mL) was
transferred into an autosampler vial, and 150 AL DMSO, free
of 1-OH-P, obtained from Pierce was added. The mixture
was vortexed, and a 100 or 250 AL aliquot of each prepared
sample was injected and analyzed by high-pressure liquid
chromatography with fluorescence detector. The modified
high-pressure liquid chromatography system separates water-
soluble impurities before elution of the desired analytes of
1-OH-P-gluc conjugate; thus, the urine clean-up step before
the high-pressure liquid chromatography analysis is not
required. A Zorbox SB-Phenyl column (250  4.6 mm ID,
5 Am; Agilent Technologies) was used at ambient temperature.
A gradient elution using 0.01 mol/L sodium dihydrogen
phosphate buffer (pH 3.5) and acetonitrile was carried out
with buffer/acetonitrile (95:5) for 5 min, followed by a gra-
dient from the 95:5 to 50:50 (buffer/acetonitrile) for 35 min,
and finally 100% acetonitrile for 10 min, at a flow rate of
1 mL/min. Fluorescence was monitored with a Shimatzu
RF-10AXL detector with the kEX fixed at 345 nm and the kEM
at 385 nm. The 1-OH-P-gluc, 1-OH-P-sulf, and free 1-OH-P
were confirmed by cochromatography with standard samples
that were obtained from the National Cancer Institute
Chemical Carcinogen Reference Standard Repositories. Quan-
tified concentrations of urinary 1-OH-P-gluc and 1-OH-P-
sulf were converted to 1-OH-P by calculation and the sum
of the three forms as determined based on 1-OH-P was
reported (Table 3), and 1-OH-P-gluc was the major (>90%)
urinary metabolite of pyrene. For checking the high-pressure
liquid chromatography column performance and the instru-
ment function, standard samples containing 1-OH-P-gluc,
1-OH-P-sulf, and 1-OH-P were included in the beginning
and in the end of each daily batch of high-pressure liquid
chromatography analysis with automatic injector. Similarly,
blank control samples were analyzed in the middle of each
batch to assure that there is no contamination (we found
that some of the commercial DMSO contain trace amount
of 1-OH-P) and no carryover from one sample to the other.
The coefficients of variation for the 1-OH-P assay were 4.3%,
6.6%, and 4.7% for 1-OH-P-gluc, 1-OH-P-sulf, and 1-OH-P,
respectively, at a concentration of 320 pg/mL of the analytes
(n = 9).
Table 2. Type and brand of cigarettes smoked by study subjects
Brand of smoked cigarettes No. smokers
Menthol Nonmenthol Male Female
AA EA AA EA
American Spirit, SP/HP (85) 1
Basic, Lt, HP (85) 1 1
Basic, Ultra Lt, (100) 1
Benson & Hedges, HP (100) 1
Benson & Hedges, U-Lt, HP (100) 1
Benson & Hedges, SP (85, 100) 1 1
Cambridge Lt, SP (100) 1
Camel U-Lt, HP (85) 1
Camel, HP (85) 1
Camel, Lt, HP (85) 5 1
Carlton, HP (100) 1
Doral, Menthol (85) 1
Eve, Lt, HP (100) 1
Kool Mild, HP (85) 1
Kool Mild, SP (100) 1 1
Kool, HP (85, 100) 3 1
Kool, SP (85) 1 1
Kool, Super Longs, SP (100) 1
Marlboro Lt, U-Lt, HP (85) 3 10 1 20
Marlboro M. HP (85, 100) 2 2 2
Marlboro, HP (85, 100) 4 24 1 10
Marlboro, HP (85) 1
Merit U-Lt, HP (85) 1
Merit, Lt, HP (85) 1
Merit, U-Lt, HP (85, 100) 1 3
Misty, U-Lt Slims (100) 1
More, SP (120) 1
Nat Sherm. (100) 1
Newport M, Lt, HP (80, 100) 1 3 4 3
Newport, HP/SP (85, 100) 36 15 43 6
Pall Mall, NON-F, SP (85) 1
Parliament Lt, SP (100) 2
Parliament, Lt, HP (85, 100) 2 2 7
Parliament, HP (100) 1
Players Lt, SP (85) 1
Players, HP (85) 1
Salem Lt, SP (85, 100) 1 1
Salem Lt, SP (85) 1
True, HP (85) 1
True, SP (100) 1
Viceroy, HP & SP (85, 100) 1 1 1 1
Virginia Slims (100) 1
VirgSlim U-Lt & Lt, HP (100) 2
Winston, FF, SP (100) 1
Winston, U-Lt, HP/SP (85) 2
Abbreviations: HP, hard pack; SP, soft pack; U-Lt, ultra light; Lt, light.
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Analyses of Urinary Nonconjugated and Glucuronide Conjugate
of NNAL and Cotinine. Urinary NNAL was determined by gas
chromatography with nitrosamine-selective detection, using
iso-NNAL as an internal standard. NNAL-glucuronide was
quantified after hydrolysis to NNAL (20). NNAL and iso-
NNAL standard samples were purchased from Toronto
Research Chemicals, Inc. Cotinine and creatinine were deter-
mined as described previously (21).
Statistical Analysis. Outcome parameters (smoking charac-
teristics, cigarette smoke emissions, and urinary biomarkers)
were compared between groups using t tests and ANCOVA
models to adjust for race and other covariates, such as body
mass index. Due to the non-normal distribution of outcomes,
all data were log transformed and are presented as geometric
means with 95% confidence intervals (95% CI). All tests were
considered statistically significant at P < 0.05.
Results
Two-hundred and sixty two healthy eligible smokers were
recruited. Five subjects were excluded from the study because
their urinary cotinine was <130 ng/mg creatinine. The subjects
were equally distributed with regard to gender and nearly
equally with regard to race (56% Euro-American and 44%
African-American). The demographic characteristics of the
smokers are summarized in Table 1. The four gender-ethnic
groups were similar in age and years of smoking. Women
tended to have begun smoking earlier than men, and Euro-
American women had significantly lower body mass than
Euro-American men. Men had smoked significantly larger
portions of their cigarettes (as indicated by shorter average
butt lengths) than women (7). Preference for mentholated
brands was greater in African-Americans (88% of females and
80% of males) than in Euro-Americans (21% of females and
27% of males).
The participants in this study smoked 45 different brands of
cigarettes, of which three were predominant (Table 2). The
menthol-containing, nonventilated Newport brand (1.4 mg
FTC nicotine/cigarette) was the type of cigarette smoked most
often by African-Americans (70.5%), whereas 23.4% of Euro-
Americans smoked nonmentholated, filter-ventilated Marlboro
(1.1 mg FTC nicotine/cigarette) and 21.7% of Euro-American
smoked Marlboro light (0.8 mg FTC nicotine/cigarette). These
three brands combined were preferred by two thirds of all
smokers.
Comparison of the Levels of Urinary Metabolites Excreted
in Smokers who Smoked Low-, Medium-, and High-Yield
Cigarettes. Classification of cigarette type as ‘‘low yield’’ (0.1-
0.8 mg nicotine/cigarette), ‘‘medium yield’’ (0.9-1.2 mg
nicotine/cigarette), and ‘‘high yield’’ (1.3-1.9 mg nicotine/
cigarette) was based on FTC nicotine levels determined from
the most recent available data (FTC, issued in 2000). The
geometric means of nicotine, NNK, and BaP emissions per
cigarette and per day obtained under human smoking
conditions and levels of urinary cotinine, total NNAL, and 1-
OH-P (before and after adjusting to delivered doses of parent
compounds) in low-, medium-, and high-yield cigarette
smokers are summarized in Table 3. The delivery of nicotine
in mainstream smoke under human smoking conditions,
measured either as mg/cigarette or mg/d, followed the same
trend as FTC-reported nicotine yields (P < 0.002). A similar
trend was observed for BaP emission, although the human
smoking condition levels of BaP in smokers of medium- and
high-yield cigarettes were not significantly different. The
average human smoking condition yield of NNK was higher
in smokers of medium-yield group (most of whom smoked
Marlboros) compared with smokers of high-yield cigarettes
(predominantly smokers of Newports; P > 0.02). The yield of
NNK in Newport cigarettes is less than in Marlboros (data not
shown).
There were no significant differences in levels of cotinine,
NNAL, and 1-OH-P among the groups smoking low-, medium-
or high-yield cigarettes, except that levels of cotinine (unad-
justed for dosage) were significantly lower (P = 0.003) in those
smoking low-yield versus medium-yield cigarette. However,
Table 3. Emissions of toxins from cigarettes in low-, medium-, and high-yield cigarette smokers and excretion of toxic
metabolites in smokers’ urine before and after adjusting for delivered doses of parent compounds in mainstream cigarette
smoke
FTC nicotine yield (geometric mean (95% CI) P*
L
c
, n = 87 M
b
, n = 109 Hx, n = 61 L versus M L versus H M versus H
Tobacco smoke emissions (human smoking conditions)
Nicotine per cigarette (mg) 1.58 (1.46-1.72) 2.15 (2.03-2.28) 2.74 (2.50-5.00) 0.0001 0.0001 0.002
Nicotine per day (mg) 24.6 (21.5-28.2) 37.5 (33.7-41.7) 42.2 (36.9-48.0) 0.0001 0.0001 0.27
NNK per cigarette (ng) 139.3 (126.4-153.6) 176.1 (160.6-193.1) 138.6 (123.5-155.5) 0.02 0.77 0.004
NNK per day (Ag) 2.17 (1.88-2.51) 3.06 (2.68-3.51) 2.13 (1.83-2.48) 0.0005 0.77 0.02
BaP per cigarette (ng) 15.7 (14.3-17.2) 20.1 (18.8-21.6) 23.4 (21.1-25.7) 0.001 0.0001 0.15
BaP per day (ng) 244.0 (211.8-281-1) 350.5 (314.9-390.0) 359.1 (312.9-412.2) 0.0001 0.0001 0.73
FTC tar per cigarette (mg) 8.04 (7.36-8.78) 15.3 (14.9-15.6) 19.1 (18.8-19.4) 0.0001 0.0001 0.0001
Urinary metabolites
Cotinine (ng/mg creatinine) 2,180 (1,800-2,640) 2,920 (2,540-3,360) 2,420 (2,010-2,910) 0.003 0.11 0.73
Cotinine (ng/mg creatinine/cpd) 138 (115-166) 168 (147-192) 158 (133-188) 0.16 0.49 0.92
Cotinine(ng/mg creat)/emitted
nicotine (mg/d)
89.4 (74.1-110) 77.8 (67.7-89.8) 57.1 (46.9-67.2) 0.81 0.06 0.09
NNAL (pmol/mg creatinine) 1.75 (1.46-2.1) 1.68 (1.41-2.0) 1.21 (1.07-1.3) 0.61 0.94 0.41
NNAL (fmol/mg creat/cpd) 110.3 (93.6-129.9) 95.6 (80.8-113.1) 79.0 (69.0-90.4) 0.85 0.44 0.65
NNAL (pmol/mg creat)/emitted
NNK (Ag/d)
0.81 (0.68-0.96) 0.55 (0.45-0.64) 0.57 (0.49-0.66) 0.04 0.05 0.54
1-OH-P (pg/mg creatinine) 378 (318-448) 396 (334-470) 347 (279-432) 0.97 0.94 0.83
1-OH-P (pg/mg creat/cpd) 23.9 (19.6-29.1) 22.7 (19.0-27.2) 22.6 (17.9-28.6) 0.55 0.53 0.96
1-OH-P (pg/mg creat)/emitted
BaP (ng/d)
1.55 (1.24-1.93) 1.13 (0.92-1.36) 0.97 (0.73-1.23) 0.03 0.008 0.54
Abbreviation: cpd, cigarettes per day.
*P values were adjusted for sex, race, and BMI. Pairwise comparisons were based on Tukey multiple comparison procedure.
cLow-yield FTC nicotine group: range, 0.1-0.8 mg/cigarette; mean, 0.66 mg/cigarette; and median, 0.65 mg/cigarette.
bMedium-yield FTC nicotine group: range, 0.9-1.2 mg/cigarette; mean, 1.12 mg/cigarette; and median, 1.1 mg/cigarette.
xHigh-yield cigarette FTC nicotine group: range, 1.3-1.9 mg/cigarette; mean, 1.41 mg/cigarette; and median, 1.4 mg/cigarette.
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there were significant differences in urinary metabolites per
unit of delivered dose of parent toxins between smokers who
smoked low- versus high-yield cigarettes (Table 3). Plots of FTC
nicotine content versus levels of urinary cotinine, NNAL, and
1-OH-P per cigarette as shown in Fig. 1A to C, respectively,
indicate that there is substantial interindividual variation in the
excretion of cotinine, NNAL, and 1-OH-P among those who
smoked cigarettes containing the same amount of nicotine
according to FTC-mandated machine smoking parameters.
Correlations between levels of FTC nicotine and each of the
three urinary biomarkers were small (r = 0.014-0.19) and none
was statistically significant.
Relationships between Delivered Doses of Cigarette
Smoke Toxins and Levels of Urinary Metabolites after
Adjustment to Toxin Exposures. Figure 2 displays mean
levels of cotinine after adjusting for creatinine and daily
delivered nicotine (under human smoking conditions) in five
subgroups that are exposed to different levels of nicotine per
day. The results clearly show that with increasing daily
delivered doses of nicotine, the excretion of cotinine per unit
of nicotine emission decreases. Similarly, the cotinine-to-
nicotine ratio in smokers who smoked V20 cigarettes per day
[118.4 F 95.4 ng/mg creatinine/mg/d (mean F SD); n = 214)]
was 3.5-fold greater than those who smoked >20 cigarettes per
day (33.8 F 39.4; n = 43; P = 0.0005).
Plots of urinary cotinine, NNAL, and 1-OH-P per unit of
delivered dose of the corresponding parent compound versus
assessed individual exposures to nicotine, NNK, and BaP,
respectively, are shown in Fig. 3A to C. With increasing
amounts of delivered dose of parent compound, the level of
urinary biomarker per unit of exposure (ratio of urinary
metabolite-to-delivered dose) decreased for all biomarkers
tested (Fig. 3A-C). A similar trend was observed in smokers
who smoked the same brand of cigarettes, namely Marlboro
(Fig. 4), with vented filter tip, as well as in smokers who
smoked Newport cigarettes that have no vented filter tip but
contain menthol (data not shown). Figure 4A shows levels of
daily delivered nicotine from mainstream smoke and urinary
cotinine for each Marlboro smoker. Fig. 4B (inset) shows a
negative correlation between cotinine-to-nicotine ratios and
Figure 1. Relationship between nicotine, measured by the FTC
method, and levels of urinary cotinine (A), total NNAL (B), and
1-OH-P (C), all expressed per milligrams (mg) creatinine in smokers’
urine (n = 257).
Figure 2. Means of cotinine-to-nicotine ratios in smokers for whom
daily delivered dose of nicotine from cigarettes are (a) <10 mg (n =
46); (b) 10.4 to 20 mg [n = 118; P = 0.06 (a versus b)]; (c) 21 to 30
mg [n = 61; P = 0.001 (a versus c) and P = 0.01 (b versus c)]; (d) 31
to 40 mg [n = 19; P < 0.0001 (a versus d) and P = 0.07 (c versus d)];
and (e) 41 to 84 mg [n = 13; P < 0.0001 (a versus e) and P = 0.1
(d versus e)].
Figure 3. Relationship between daily delivered emissions of select
tobacco smoke toxins as determined by machine smoking mimicking
human smoking conditions (HSC ) and corresponding urinary
metabolites per unit of daily emissions of parent toxin in smokers.
A. Cotinine/nicotine versus nicotine. B. NNAL/NNK versus NNK. C.
1-OH-P/BaP versus BaP. r, logarithmic regression.
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daily delivered doses of nicotine in subgroups of smokers who
smoked Marlboro (r = 0.59; linear regression) and
corresponding r value for Newport was 0.37 (data not
shown).
Discussion
A great body of evidence suggests that yields per cigarette of
tar, nicotine, and other smoke constituents, derived from
machine smoking with FTC/International Standards Organi-
zation protocols, do not provide valid estimates of human
exposure and risk for tobacco-related disease (National Cancer
Institute Monograph No. 13). Urinary metabolites of tobacco
smoke toxins were widely used as biomarkers for the
assessment of direct and passive exposure to cigarette smoke
(8, 10, 11). Urinary metabolites are generally affected by
interindividual differences in metabolism; the intensity of
exposure may also modify the metabolism through altered
expression of relevant enzymes.
Levels of urinary cotinine, total NNAL, and 1-OH-P were
not significantly different in smokers who smoked low-yield
cigarettes, as ranked by the FTC machine smoking method, by
comparison to those who smoked high-yield cigarettes (Fig. 1;
Table 3), which are consistent with previous findings (8).
However, there were significant differences in delivered doses
of nicotine, NNK, and BaP from mainstream smoke when
smokers’ customary cigarettes were machine smoked under
conditions matching the habits of each subject in the study.
Delivered dosages of nicotine and BaP in subjects who smoked
low-yield cigarettes were lower than those who smoked high-
yield cigarettes. Hence, smokers of low-yield cigarettes excrete
more metabolites per delivered dosage of toxins than those
who smoke high-yield cigarettes (Table 3). The mean ratios of
cotinine-to-nicotine, NNAL-to-NNK, and 1-OH-P-to-BaP were
64%, 70%, and 62% higher, respectively, in smokers of low-
yield cigarettes than in those who smoked high-yield cigarettes
(Table 3) and the ratios of metabolites-to-parent compounds
decreased with increasing delivered doses of the parent toxin
(Figs. 2, 3, and 4B).
Smokers’ exposure to toxins is affected by the type/brand of
cigarettes used, individual smoking behavior, and by the
number of cigarettes smoked per day. To adjust the role of
cigarette design factors on interindividual variability of
urinary biomarkers, we compared relationships of delivered
doses of carcinogens and urinary metabolites among smokers
who smoked the same brand of cigarettes, namely Marlboro, a
popular brand of cigarette in the United States that features
ventilation holes in its filter tip and is smoked mostly by Euro-
Americans. Again, an inverse relationship was observed
between cotinine-to-nicotine ratios and delivered daily doses
of nicotine (Fig. 4B, inset). Filter vents are designed to dilute
mainstream smoke and produce less smoke in the burning
cone that changes the chemical composition of the combustion
product (5). Some smokers block filter vents with either
fingertips or lips; exposure to cigarette smoke toxins increases
slightly when filter vents are blocked. Furthermore, to
eliminate the filter vent blocking factor, we investigated
another popular brand of cigarette that does not have filter
ventilation, namely the mentholated Newport that is smoked
mostly by African-Americans, and we found that the same
trend persists; the intake, conversion, and excretion of toxins to
urinary metabolites decrease with increased delivered dosage
(data not shown).
Smokers who inhaled 10 to 20 mg nicotine/d excreted about
twice as much cotinine per unit of nicotine than those who
inhaled 31 to 40 mg nicotine/d (Fig. 2). The current study
indicates that increasing the number of cigarettes smoked per
day results in a decreased ratio of cotinine-to-nicotine; the
mean of cotinine per unit of nicotine in the subgroup smoking
V20 cigarettes per day was 3.5-fold higher than that in those
who smoked >20 cigarettes per day.
Our findings suggest that a higher degree of exposure may
also alter intake and metabolism of other tobacco smoke toxins
and excretion of urinary metabolites. There are many
Figure 4. A. Levels of daily delivered
nicotine in smokers who smoked Marl-
boro (1.1 mg FTC nicotine/cigarette;
white columns) and urinary cotinine/100
(black columns). Inset, the relationship
between daily nicotine emissions from
cigarettes and excretion of urinary coti-
nine. B. Levels of daily delivered nicotine
(white columns) and the ratios of coti-
nine-to-daily delivered dosage of nicotine
(black columns).
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compounds in tobacco smoke that could alter the metabolism
of nicotine and other carcinogens and down-regulate several
enzyme activities. Benowitz and Jacob (22) have shown that
nicotine metabolism is decreased in smokers versus non-
smokers. Similarly, Lee et al. (23) have shown that smokers
have slower nicotine clearance after an overnight abstinence
period compared with a 7-day abstinence period. Schoedel
et al. (24) have shown that long-term, in vivo nicotine treatment
of African green monkeys decreased in vitro nicotine metab-
olism and the expression of hepatic CYP2A6 protein. CYP2A6
is a primary enzyme that activates nicotine to cotinine, as well
as NNK to NNAL, suggesting that nicotine may decrease its
own metabolism by decreasing expression of the nicotine-
metabolizing enzyme CYP2A6. Thus, nicotine or other
constituents of tobacco smoke may change the metabolism or
pharmacokinetics with increasing nicotine or carcinogen
intake at higher intensity of tobacco smoke exposure.
The current findings agree with other published studies.
Law et al. (25) found that the ratio of serum hemoglobin to
number of cigarettes smoked per day decreased with
increasing smoking intensity. Vineis et al. (26, 27) have found
that the dose-response for cancers of the lung and bladder is
leveling off in heavy smokers who have regularly consumed 20
to 40 cigarettes per day. This apparent dose-response ‘‘ceiling’’
was originally reported for bladder cancer by Wynder and
Stellman (28). In a large case-control study of lung cancers
using a novel exposure rate model, Lubin and Caporaso (29)
have shown a direct intensity rate effect at low smoking
intensities and an inverse intensity rate effect at higher
intensities. Haiman et al. (30) have found significant differ-
ences in the association between cigarette smoking and the risk
of lung cancer among five self-reporting ethnic and racial
populations. These differences were not observed among
heavy smokers (>30 cigarettes per day).
Our observation suggests that a slight reduction of the
number of cigarettes smoked per day or changing type of
cigarettes to those with a slightly lower yield may affect and
slightly increase the overall intake of carcinogens and/or
metabolism and thus will not have much potential to reduce
toxic metabolites so as to produce a significant health effect.
Indeed, recent assessments of morbidity and mortality suggest
that low-yield products are associated with far less health
benefit (31).
The way each cigarette is smoked by an individual governs
mainstream smoke yields and, consequently, the smoker’s
exposure to harmful compounds. Our studies have shown that
interindividual variation of carcinogen intake from main-
stream smoke differs by f4-fold due to smoking behavior
(7, 32, 33).
There were some limitations in the current PAH study. BaP
was used as a biomarker of exposure to PAHs, whereas 1-OH-
P, a metabolite of pyrene, was used as a biomarker of PAH
exposures. The reason for this substitution is that the
concentrations of BaP metabolites in urine are low so that
they are not sufficiently sensitive as a biomarker of PAH
exposure (34). By contrast, pyrene, which is a dominant
compound in the PAH mixture at a concentration of f50 to
270 ng/cigarette in mainstream smoke, is mainly metabolized
to the intermediary 1-OH-P, which forms predominantly 1-
OH-P-gluc and, to much smaller extent, a sulfate conjugate, all
of which are excreted in urine (35). Because the introduction of
the urinary 1-OH-P as a biomarker of human PAH exposure,
many studies have confirmed that 1-OH-P is a valid and
sensitive indicator of PAH exposure (36, 37). The correlation
between BaP exposure from mainstream cigarette smoke and
urinary 1-OH-P in the current study is r = 0.48 (n = 231).
In conclusion, our data indicate that delivered doses of
toxins from mainstream smoke affect the intake, metabolism,
and excretion of metabolites in urine; at lower exposure, more
metabolites appear in the urine than at higher exposures per
unit of exposure. Thus, when urinary metabolites are used as
biomarkers of exposure to toxic compounds of cigarette
smoke, several factors, such as interindividual variation in
metabolism and intensity of exposure, and other factors that
are not presented in this paper, such as menthol-presenting
cigarettes and gender (32), need to be taken in consideration.
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